GLP-1 receptor agonists are recommended in the treatment of PCOS because of the relationship between PCOS and other insulin resistance-related clinical manifestations, such as uncontrolled weight gain, high BMI, and unstable lipid panels [4,7,8]. This evidence concerns the gene GLP1R and polycystic ovary syndrome.